Keytruda® (pembrolizumab) – Expanded indication
May 10, 2017 – Merck announced the FDA approval of Keytruda (pembrolizumab) in combination with Alimta® (pemetrexed) and carboplatin, as first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
Download PDF
